Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Inozyme Pharma, Inc. INZY
$6.21
-$0.22 (-3.57%)
На 18:02, 12 мая 2023
+544.12%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
304607880.00000000
-
week52high
6.99
-
week52low
0.99
-
Revenue
0
-
P/E TTM
-3
-
Beta
1.08567400
-
EPS
-1.74000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 12:30
Описание компании
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Jefferies | Hold | 26 мая 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 11 мая 2022 г. |
| Wedbush | Outperform | Outperform | 16 мар 2022 г. |
| HC Wainwright & Co. | Buy | 07 февр 2022 г. | |
| Needham | Buy | 29 ноя 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Bjarke Henric Bjorn | A | 105441 | 21500 | 15 дек 2022 г. |
| Bjarke Henric Bjorn | A | 83941 | 3315 | 30 сент 2022 г. |
| Bolte Axel | A | 261890 | 3315 | 30 сент 2022 г. |
| Mathers Edward T | A | 9367 | 9367 | 10 июн 2022 г. |
| Treco Douglas A | A | 9367 | 9367 | 10 июн 2022 г. |
| Sullivan Lynne Marie | A | 9367 | 9367 | 10 июн 2022 г. |
| Hopfner Robert Lorne | A | 9367 | 9367 | 10 июн 2022 г. |
| Edwards Martin | A | 9367 | 9367 | 10 июн 2022 г. |
| Bhagat Sarah M | A | 9367 | 9367 | 10 июн 2022 г. |
| DIAZ REINALDO M | A | 9367 | 9367 | 10 июн 2022 г. |
Новостная лента
Inozyme Pharma to Participate in Upcoming Investor Conferences
GlobeNewsWire
07 ноя 2022 г. в 07:30
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will participate in the following investor conferences:
Inozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
06 сент 2022 г. в 07:30
BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference. The prerecorded presentation will become available on-demand on Monday, September 12, 2022, at 7:00 AM ET.
Inozyme Pharma Post Encouraging Early Data From Genetic Disorder Trial
Benzinga
20 июл 2022 г. в 11:04
Inozyme Pharma Inc (NASDAQ: INZY) has announced preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three subjects in the Phase 1 portion of its ongoing Phase 1/2 trial of INZ-701 in ABCC6 Deficiency, which presents as pseudoxanthoma elasticum (PXE) in older.
How Much Upside is Left in Inozyme Pharma, Inc. (INZY)? Wall Street Analysts Think 309%
Zacks Investment Research
24 июн 2022 г. в 11:40
The consensus price target hints at a 308.5% upside potential for Inozyme Pharma, Inc. (INZY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Inozyme Pharma to Present at the 2022 Jefferies Healthcare Conference
GlobeNewsWire
01 июн 2022 г. в 07:30
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will present at the Jefferies Healthcare Conference. The presentation will take place on Wednesday, June 8, 2022 at 2:30 PM ET.